Application of kaempferol to drugs for treating osteoarthritis

A technology for treating osteoarthritis and drugs, applied in the field of medicine, can solve the problems that there are no references in literature and research, and achieve the effects of promoting osteoclast formation, H-type blood vessel formation, and vascularization

Inactive Publication Date: 2019-03-12
SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] However, whether kaempferol can be used to treat osteoarthritis, and how it intervenes in osteoarthritis, there are no literatures and studies mentioned

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of kaempferol to drugs for treating osteoarthritis
  • Application of kaempferol to drugs for treating osteoarthritis
  • Application of kaempferol to drugs for treating osteoarthritis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0045] Embodiment 1, primary separation and purification technology of nerve cells

[0046] 4-week-old male SPRAGUE-DAWLEY rats were euthanized by carbon dioxide gas chamber and then dissected to expose the dorsal root ganglia. After the dorsal root ganglia were removed, they were digested with 0.25% trypsin and 2 mg / ml type I collagenase for 45 minutes. It was then placed in 15% Percoll and centrifuged at 200g gradient for 5 minutes. Purified dorsal root ganglion cells were obtained by differential attachment method. figure 1 Among them, A is the general morphology of the DRG in the rat animal model, and B is the DRG cells purified by the primary isolation technique. figure 1 It shows that through the above techniques, we can sieve out the impurity cells and obtain pure primary dorsal root ganglion cells. This has laid a necessary and good foundation for the following experiments.

Embodiment 2

[0047] Example 2. Second-generation whole-transcriptome sequencing technology screening for significantly up-regulated neurosecretory products

[0048] The extracted and purified dorsal root ganglion cells were respectively stimulated with 0 and 10 ng / ml interleukin-1β for 24 hours. Total RNA of primary cells of dorsal root ganglion was extracted with TRIzol kit. Agilent 4200 TapeStation system was used to control the quality of samples, Illumina PE150 was used to obtain paired-end sequencing results (Paired-end reads), and the HISAT2 program was used to match the results with the genome of UCSC rats (UCSC Rn6 rat reference genome). Next, the HISAT2 program was used to measure the abundance of transcripts, and genes and transcriptomes with RPKM less than 5 were eliminated. The heat map was generated by the R language program (3.0.2). figure 2 Genes significantly changed in primary DRG cells upon IL-1β stimulation are shown.

[0049] figure 2 It was shown that through the...

Embodiment 3

[0050] Example 3, Effects of Dorsal Root Ganglion Conditioned Medium on Endothelial Cell Vascularization (A) and Osteoclast Formation (B)

[0051] The dorsal root ganglion cells were cultured in medium containing 0, 1, 10, and 100 ng / ml interleukin-1β (IL-1β) for 24 hours, washed three times with phosphate buffer, and then added with serum-free medium to continue culturing for 24 hours. hours, centrifuged to collect the conditioned medium for later use.

[0052] Human umbilical vein endothelial cells (HUVEC) cells were seeded at a density of 600,000 / well in a six-well plate pre-coated with 30% Matrigel, corresponding to four groups of conditioned medium, and 100ng / ml conditioned medium + 1:2000 Anti-Galectin-1 (galectin-1 antibody) groups were treated for 6 hours. After staining with 2 μM calcein for 15 minutes, the angiogenesis of endothelial cells was observed with a fluorescence microscope.

[0053] Bone marrow macrophages were seeded in a 96-well plate at a density of 10...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of kaempferol to drugs for treating osteoarthritis. Kaempferol decreases expression of anti-galectin-1 in sensory neurone by inhibiting NF-kappa B and MAPK signal pathway activated in the inflammatory environment, reducing expression of c-Fos, c-Jun and delta FosB in sensory neurone and inhibiting combination activity of transcription factor activator protein-1(AP-1) and DNA, expression of anti-galectin-1 in nerve cell is reduced, and accordingly development of osteoarthritis is relieved. The invention provides a new drug for clinic treatment of osteoarthritis, and meanwhile states the mechanism of the novel treatment drug. New thought and experiences are provided for better understanding the pathological process of osteoarthritis and developing the drugs for treating osteoarthritis in the future.

Description

technical field [0001] The invention relates to the field of medicine, in particular to the application of kaempferol in medicine for treating osteoarthritis. Background technique [0002] Osteoarthritis is a joint degenerative disease that seriously affects the quality of life of patients and causes a huge economic burden on patients, families and society. [0003] At present, for bone and joint patients, mainly based on the severity of the patient's condition, lesion location and symptoms, the combination of medical and surgical treatment is adopted, and individualized and basic treatment, drug treatment, restorative treatment, and reconstructive treatment are step-by-step treatment methods. Drug therapy has no surgical risks and complications, and has less economic burden on patients. Compared with restorative therapy and reconstruction therapy, it is suitable for patients with more extensive and earlier lesions of osteoarthritis, and has broad and important application v...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P19/02A61P19/00
CPCA61K31/352A61P19/00A61P19/02
Inventor 汤亭亭梅竞天乔涵周峰
Owner SHANGHAI NINTH PEOPLES HOSPITAL SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap